This dual mechanism involving both the tumor cells’ autocrine signaling and macrophage recruitment contributes to the poor therapeutic response and highlights the potential benefit of CCR2 inhibitors in treating ovarian cancer (35). This evidence concerns the gene CCR2 and ovarian carcinoma.